The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population

Respiratory Medicine

Volumn 102, Issue 9, 2008, Pages 1248-1256

  Menzin, Joseph ^a   Boulanger, Luke ^a   Marton, Jeno ^b   Guadagno, Lisa ^a   Dastani, Homa ^c   Dirani, Riad ^b   Phillips, Amy ^c   Shah, Hemal ^c  

^a Boston Health Economics Inc   (United States)

^b PFIZER INC   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

COPD; Economics; Treatment costs

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; RESPIRATORY TRACT AGENT; XANTHINE DERIVATIVE;

AGED; ARTICLE; BILLING AND CLAIMS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PRIORITY JOURNAL; UNITED STATES;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; DIRECT SERVICE COSTS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MEDICARE; PATIENT ACCEPTANCE OF HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 48349119174     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.04.009     Document Type: Article

References (27)

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2005. Available at: www.goldcopd.org; 2005 [accessed 22.11.05].
2. National Institutes of Health, National Heart, Lung, and Blood Institute. Data fact sheet: chronic obstructive pulmonary disease (COPD). Washington, D.C.: NIH; 2003. Report No.: 03-5229.
3. World Health Organization. Chronic obstructive pulmonary disease (COPD). Available at: (2006 November). http://www.who.int/mediacentre/factsheets/fs315/en/index.html [accessed 20.08.07]
4. American Lung Association. Chronic obstructive pulmonary disease (COPD) fact sheet (chronic bronchitis and emphysema). Available at: (2005 July). http://www.lungusa.org/site/pp.asp?c = dvLUK9O0E&b = 35020 [accessed 6.03.06]
5. Kumar S., and Gross N.J. The global initiative for COPD: what you need to know; smoking cessation is still the most effective way to reduce risk (chronic obstructive pulmonary disease). J Respir Dis 23 11 (2002) 549-556 [accessed 8.12.03]
6. Wouters E.F. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 97 Suppl. C (2003 Mar) 3-14
7. Ward M.M., Javitz H.S., Smith W.M., and Bakst A. Direct medical costs of chronic obstructive pulmonary disease in the USA. Respir Med 94 11 (2000 Nov) 1123-1129
8. Grasso M.E., Weller W.E., Shaffer T.J., Diette G.B., and Anderson G.F. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 1 (1998 Jul) 133-138
9. Strassels S.A., Smith D.H., Sullivan S.D., and Mahajan P.S. The costs of treating COPD in the United States. Chest 119 2 (2001 Feb) 344-352
10. Yelin E., Trupin L., Cisternas M., Eisner M., Katz P., and Blanc P. A national study of medical care expenditures for respiratory conditions. Eur Respir J 19 3 (2002 Mar) 414-421
11. Marton J.P., Boulanger L., Friedman M., Dixon D., Wilson J., and Menzin J. Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. Respir Med 100 6 (2006 Jun) 996-1005
12. Wilson L., Devine E.B., and So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 94 3 (2000 Mar) 204-213
13. Mapel D.W., Hurley J.S., Frost F.J., Petersen H.V., Picchi M.A., and Coultas D.B. Healthcare utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 160 17 (2000 Sep 25) 2653-2658
14. Miller J.D., Foster T., Boulanger L., Chace M., Russell M.W., Marton J.P., et al. Direct costs of COPD in the U.S.: an analysis of medical expenditure panel survey (MEPS) data. COPD 2 3 (2005) 311-318
15. Goldman D.P., Joyce G.F., and Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298 1 (2007 Jul 4) 61-69
16. Henry J., and Kaiser Family Foundation. Medicare (fact sheet): medicare spending and financing. Available at: (2007). www.kff.org [accessed 2.10.07]
17. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 5 (1987) 373-383
18. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Am J Respir Crit Care Med 45 6 (1992 Jun) 613-619
19. Foster T., Miller J.D., Marton J.P., Caloyeras J.P., Russell M.W., and Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD 3 4 (2006) 211-218
20. Miravitlles M., Murio C., Guerrero T., and Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123 3 (2003 Mar) 784-791
21. Andersson F., Borg S., Jansson S.A., Jonsson A.C., Ericsson A., Prutz C., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 96 9 (2002 Sep) 700-708
22. Simoens S., Decramer M., De C.S., Celis G., and Laekeman G. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations. Int J Clin Pract 61 2 (2007 Feb) 200-206
23. Oostenbrink J.B., and Rutten-van Molken M.P. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 98 9 (2004 Sep) 883-891
24. Jansson S.A., Andersson F., Borg S., Ericsson A., Jonsson E., and Lundback B. Costs of COPD in Sweden according to disease severity. Chest 122 6 (2002 Dec) 1994-2002
25. Incalzi R.A., Corsonello A., Pedone C., Masotti G., Bellia V., Grassi V., et al. From Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines to current clinical practice: an overview of the pharmacological therapy of stable chronic obstructive pulmonary disorder. Drugs Aging 23 5 (2006) 411-420
26. Incorvaia C., Pravettoni C., and Riario-Sforza G.G. Drug treatment of asthma and COPD in the general practice: adherence to international guidelines. Giorn It Allergol Immunol Clin 15 (2005) 111-115
27. Henry J., and Kaiser Family Foundation. Medicare advantage April 2005 fact sheet. Henry J Kaiser Family Foundation. Available at: (2006). http://kaiserfamilyfoundation.org/medicare/upload/Medicare-Advantage-Apr il-2005-Fact-Sheet.pdf [accessed 18.09.06]